We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Palatin Technologies Inc is a part of the healthcare sector. The company is engaged in developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with unmet medical needs and commercial potential. Its programs are based on molecules that modulate the activity of the me... Palatin Technologies Inc is a part of the healthcare sector. The company is engaged in developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with unmet medical needs and commercial potential. Its programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its main product in clinical development is bremelanotide, which treats hypoactive sexual desire disorder, which is a type of female sexual dysfunction. Show more
Palatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease (DED) Clinical Data Results Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2024 PR Newswire CRANBURY, N.J...
Palatin Announces Results of PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED) PR Newswire CRANBURY, N.J., Feb. 28, 2024 On an Intent-to-Treat Analysis...
Palatin Reports Second Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update PR Newswire CRANBURY, N.J., Feb. 15, 2024 Palatin's Focus is Solely on the Development of its...
Palatin to Report Second Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on February 15, 2024 PR Newswire CRANBURY, N.J., Feb. 9, 2024 CRANBURY, N.J., Feb. 9, 2024...
Palatin Announces Database Lock for PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED) PR Newswire CRANBURY, N.J., Feb. 5, 2024 Top-Line Results Expected in...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.15 | -7.53768844221 | 1.99 | 2.0279 | 1.81 | 251694 | 1.8794584 | CS |
4 | 0.27 | 17.1974522293 | 1.57 | 2.88 | 1.51 | 890655 | 1.98220631 | CS |
12 | -2.17 | -54.114713217 | 4.01 | 5.65 | 1.46 | 727812 | 2.63288356 | CS |
26 | 0.09 | 5.14285714286 | 1.75 | 5.65 | 1.46 | 476742 | 2.71850001 | CS |
52 | -0.85 | -31.5985130112 | 2.69 | 5.65 | 1.43 | 278351 | 2.64182611 | CS |
156 | 1.29 | 234.545454545 | 0.55 | 8.6 | 0.1811 | 1278878 | 0.77298978 | CS |
260 | 0.74 | 67.2727272727 | 1.1 | 8.6 | 0.1811 | 1819991 | 0.8087395 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions